{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T09:42:28Z","timestamp":1785404548963,"version":"3.56.0"},"reference-count":58,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NIH","award":["AI23596"],"award-info":[{"award-number":["AI23596"]}]},{"name":"NIH","award":["HL109561"],"award-info":[{"award-number":["HL109561"]}]},{"name":"NIH","award":["DOD BC085077 (MEM)"],"award-info":[{"award-number":["DOD BC085077 (MEM)"]}]},{"award":["AI23596"],"award-info":[{"award-number":["AI23596"]}],"id":[{"id":"https:\/\/ror.org\/05h1kgg64","id-type":"ROR","asserted-by":"publisher"}]},{"award":["HL109561"],"award-info":[{"award-number":["HL109561"]}],"id":[{"id":"https:\/\/ror.org\/05h1kgg64","id-type":"ROR","asserted-by":"publisher"}]},{"award":["DOD BC085077 (MEM)"],"award-info":[{"award-number":["DOD BC085077 (MEM)"]}],"id":[{"id":"https:\/\/ror.org\/05h1kgg64","id-type":"ROR","asserted-by":"publisher"}]},{"name":"Ingalls Foundations"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Solid tumors typically expand in a \u201ccold\u201d immunosuppressive tumor microenvironment (TME) and resist killing by CAR T cells or conventional therapy. Herein, we show that intratumoral injection of C3a and C5a receptor 1 (C3ar\/C5ar1) pharmaceutical antagonists in an in situ forming implant (ISFI) can robustly suppress such tumors. Antagonizing autocrine C3ar\/C5ar1 signaling in eight human and murine cancers of diverse lineages was universally anti-mitotic and pro-apoptotic in vitro, and growth-repressive in vivo. In contrast to i.p. administration of C3ar\/C5ar1 antagonists to tumor-bearing mice, injecting the antagonists intratumorally in slow release poly (lactic-co-glycolic acid) (PLGA) polymer caused near-complete tumor elimination. The focused blockade of C3ar\/C5ar1 GPCR signaling in an intratumoral ISFI opposed solid cancers by jointly repressing cancer cell viability\/growth, tumor-associated angiogenesis, and myeloid-derived suppressor cell (MDSC) recruitment. Thus, the sustained blockade of C3ar\/C5ar1 signaling in an intratumoral ISFI uninterruptedly disrupts three processes essential for solid cancer growth while avoiding adverse effects on other cell types. Our findings may apply to multiple cancer types in which discrete tumor masses can be targeted.<\/jats:p>","DOI":"10.3390\/cells15110971","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T10:19:52Z","timestamp":1779877192000},"page":"971","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Intratumoral C3ar\/C5ar1 Antagonists Imbedded in an In Situ Forming Implant Can Robustly Suppress Solid Tumors"],"prefix":"10.3390","volume":"15","author":[{"given":"Young","family":"Choi","sequence":"first","affiliation":[{"name":"Institute of Pathology, Case Western Reserve University, Cleveland, OH 44106, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Konrad","sequence":"additional","affiliation":[{"name":"Institute of Pathology, Case Western Reserve University, Cleveland, OH 44106, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elliot","family":"Pohlmann","sequence":"additional","affiliation":[{"name":"Institute of Pathology, Case Western Reserve University, Cleveland, OH 44106, USA"},{"name":"Virginia Tech Carilion School of Medicine and Research Institute, Roanoke, VA 24016, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Abenojar","sequence":"additional","affiliation":[{"name":"Virginia Tech Carilion School of Medicine and Research Institute, Roanoke, VA 24016, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3913-7066","authenticated-orcid":false,"given":"Agata","family":"Exner","sequence":"additional","affiliation":[{"name":"Virginia Tech Carilion School of Medicine and Research Institute, Roanoke, VA 24016, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Medof","sequence":"additional","affiliation":[{"name":"Institute of Pathology, Case Western Reserve University, Cleveland, OH 44106, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"153100","DOI":"10.1016\/j.imbio.2025.153100","article-title":"Genetic variants in complement-related genes: Potential implications for cancer risk and progression","volume":"230","author":"Fung","year":"2025","journal-title":"Immunobiology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"101951","DOI":"10.1016\/j.smim.2025.101951","article-title":"Interplay between the complement system and other immune pathways in the tumor microenvironment","volume":"78","author":"Garlanda","year":"2025","journal-title":"Semin. Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"101963","DOI":"10.1016\/j.smim.2025.101963","article-title":"Harnessing complement biomarkers for precision cancer care","volume":"78","author":"Hamidi","year":"2025","journal-title":"Semin. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e51767","DOI":"10.1002\/eji.202451767","article-title":"Pro- and Anti-Inflammatory Role of Complement in Cancer","volume":"55","author":"Pal","year":"2025","journal-title":"Eur. J. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1084\/jem.20041967","article-title":"Decay-accelerating factor moduLates induction of T cell immunity","volume":"201","author":"Heeger","year":"2005","journal-title":"J. Exp. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1111\/j.1600-6143.2009.02723.x","article-title":"Primed CD8(+) T-cell responses to allogeneic endothelial cells are controlled by local complement activation","volume":"9","author":"Raedler","year":"2009","journal-title":"Am. J. Transplant."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.immuni.2008.02.001","article-title":"Locally produced complement fragments C5a and C3a provide both costimuLatory and survival signals to naive CD4+ T cells","volume":"28","author":"Strainic","year":"2008","journal-title":"Immunity"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e2350820","DOI":"10.1002\/eji.202350820","article-title":"The complement system as a target in cancer immunotherapy","volume":"54","author":"Merle","year":"2024","journal-title":"Eur. J. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"5882","DOI":"10.4049\/jimmunol.180.9.5882","article-title":"IFN-gamma and IL-17 production in experimental autoimmune encephalomyelitis depends on local APC-T cell complement production","volume":"180","author":"Liu","year":"2008","journal-title":"J. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"aad1210","DOI":"10.1126\/science.aad1210","article-title":"T helper 1 immunity requires complement-driven NLRP3 inflammasome activity in CD4(+) T cells","volume":"352","author":"Arbore","year":"2016","journal-title":"Science"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1182\/blood-2008-04-151068","article-title":"Locally produced C5a binds to T cell-expressed C5aR to enhance effector T-cell expansion by limiting antigen-induced apoptosis","volume":"112","author":"Lalli","year":"2008","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/ni.2499","article-title":"Absence of signaling into CD4(+) cells via C3aR and C5aR enables autoinductive TGF-beta1 signaling and induction of Foxp3(+) reguLatory T cells","volume":"14","author":"Strainic","year":"2013","journal-title":"Nat. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.ajpath.2019.04.008","article-title":"CD55 Is Essential for CD103(+) Dendritic Cell Tolerogenic Responses that Protect against Autoimmunity","volume":"189","author":"Strainic","year":"2019","journal-title":"Am. J. Pathol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/ajt.15072","article-title":"C5aR1 reguLates migration of suppressive myeloid cells required for costimuLatory blockade-induced murine allograft survival","volume":"19","author":"Llaudo","year":"2019","journal-title":"Am. J. Transplant."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"101976","DOI":"10.1016\/j.smim.2025.101976","article-title":"Local and Cell-intrinsic complement: The new player in cancer progression","volume":"79","author":"Revel","year":"2025","journal-title":"Semin. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1053\/gast.2002.37075","article-title":"Stat3 and NF-kappaB activation prevents apoptosis in pancreatic carcinogenesis","volume":"123","author":"Greten","year":"2002","journal-title":"Gastroenterology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"20858","DOI":"10.1074\/jbc.M310643200","article-title":"The pro-apoptotic protein Bim is a convergence point for cAMP\/protein kinase A- and glucocorticoid-promoted apoptosis of lymphoid cells","volume":"279","author":"Zhang","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1096\/fj.201900677R","article-title":"RTK signaling requires C3ar1\/C5ar1 and IL-6R joint signaling to repress dominant PTEN, SOCS1\/3 and PHLPP restraint","volume":"34","author":"Strainic","year":"2020","journal-title":"FASEB J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"jcs.219352","DOI":"10.1242\/jcs.219352","article-title":"VEGFR2 survival and mitotic signaling depends on joint activation of associated C3ar1\/C5ar1 and IL-6R-gp130","volume":"132","author":"Hwang","year":"2019","journal-title":"J. Cell. Sci."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Sobczynska-Rak, A., Zylinska, B., Nowicka, B., Rak, E., and Rzepka, T. (2025). Role and Mechanisms of Angiogenesis in Tumours. Biology, 14.","DOI":"10.3390\/biology14070756"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"100778","DOI":"10.1016\/j.gastha.2025.100778","article-title":"VascuLar Endothelial Growth Factor Receptor 2-Targeted Therapy Suppresses the Progression of Alpha-Fetoprotein-Positive HepatocelluLar Carcinoma After Combination Therapy with Anti-Programmed Death-Ligand 1 and Anti-VascuLar Endothelial Growth Factor-A Antibodies","volume":"5","author":"Sugiyama","year":"2026","journal-title":"Gastro Hep Adv."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1007\/s12672-025-03797-1","article-title":"Microenvironmental reguLation and remodeling of breast cancer angiogenesis: From basic mechanisms to clinical therapeutic implications","volume":"16","author":"Zhou","year":"2025","journal-title":"Discov. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1161\/ATVBAHA.110.205559","article-title":"The intrinsic complement reguLator decay-accelerating factor moduLates the biological response to vascuLar injury","volume":"30","author":"Sakuma","year":"2010","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"102511","DOI":"10.1016\/j.coi.2024.102511","article-title":"Navigating the metabolic landscape of reguLatory T cells: From autoimmune diseases to tumor microenvironments","volume":"92","author":"Harm","year":"2025","journal-title":"Curr. Opin. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"113952","DOI":"10.1016\/j.intimp.2024.113952","article-title":"Unleashing the Power of immune Checkpoints: A new strategy for enhancing Treg cells depletion to boost antitumor immunity","volume":"147","author":"Li","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1038\/ni.1655","article-title":"ModuLation of the antitumor immune response by complement","volume":"9","author":"Markiewski","year":"2008","journal-title":"Nat. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"6367","DOI":"10.1158\/0008-5472.CAN-09-1918","article-title":"Unwelcome complement","volume":"69","author":"Markiewski","year":"2009","journal-title":"Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"278","DOI":"10.4049\/jimmunol.1700339","article-title":"TLR-Induced Murine Dendritic Cell (DC) Activation Requires DC-Intrinsic Complement","volume":"199","author":"Sheen","year":"2017","journal-title":"J. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.ejpb.2004.03.003","article-title":"In situ forming parenteral drug delivery systems: An overview","volume":"58","author":"Packhaeuser","year":"2004","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1080\/20468954.2025.2470103","article-title":"PLGA and cancer: A comprehensive patent-based review on the present state of art","volume":"13","author":"Nath","year":"2025","journal-title":"Pharm. Pat. Anal."},{"key":"ref_31","first-page":"141","article-title":"New methods for direct delivery of chemotherapy for treating brain tumors","volume":"79","author":"Sawyer","year":"2006","journal-title":"Yale J. Biol. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/j.juro.2006.06.079","article-title":"Management of locally advanced prostate cancer: Past, present, future","volume":"176","author":"Swanson","year":"2006","journal-title":"J. Urol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1001\/jama.296.19.2329","article-title":"Adjuvant radiotherapy for pathologically advanced prostate cancer: A randomized clinical trial","volume":"296","author":"Thompson","year":"2006","journal-title":"Jama"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0169-409X(97)00036-7","article-title":"Polymeric implants for cancer chemotherapy","volume":"26","author":"Saltzman","year":"1997","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0168-3659(02)00008-1","article-title":"Biodegradable injectable in situ forming drug delivery systems","volume":"80","author":"Hatefi","year":"2002","journal-title":"J. Control Release"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"In, H., Park, M., Lee, H., and Han, K.H. (2025). Immune Cell Engagers: Advancing Precision Immunotherapy for Cancer Treatment. Antibodies, 14.","DOI":"10.3390\/antib14010016"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Zhao, H., Huang, S., Wu, J., Lu, Y., Zou, Y., Zeng, H., Li, C., Wang, J., Zhang, X., and Duan, S. (2025). Efficacy and safety of first-line PD-1\/PD-L1 inhibitor in combination with CTLA-4 inhibitor in the treatment of patients with advanced non-small cell lung cancer: A systemic review and meta-analysis. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1515027"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e70115","DOI":"10.1111\/echo.70115","article-title":"MuLtimodality Imaging and Immune-Related Adverse Events During Immune Checkpoint Inhibitors Treatment: Where Do We Stand?","volume":"42","author":"Crosio","year":"2025","journal-title":"Echocardiography"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10555-025-10246-6","article-title":"Monocyte-related markers as predictors of immune checkpoint inhibitor efficacy and immune-related adverse events: A systematic review and meta-analysis","volume":"44","author":"Ezdoglian","year":"2025","journal-title":"Cancer Metastasis Rev."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1172\/JCI61019","article-title":"Antigen-presenting cell-derived complement moduLates graft-versus-host disease","volume":"122","author":"Kwan","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.4049\/jimmunol.2300628","article-title":"Critical Role of CD55 in Controlling Wound Healing","volume":"212","author":"Kang","year":"2024","journal-title":"J. Immunol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"308","DOI":"10.4049\/jimmunol.155.1.308","article-title":"Expression of functional receptors for human C5a anaphylatoxin (CD88) on the human hepatocelluLar carcinoma cell line HepG2. StimuLation of acute-phase protein-specific mRNA and protein synthesis by human C5a anaphylatoxin","volume":"155","author":"Buchner","year":"1995","journal-title":"J. Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1158\/1078-0432.CCR-12-1204","article-title":"Enhancement of human cancer cell motility and invasiveness by anaphylatoxin C5a via aberrantly expressed C5a receptor (CD88)","volume":"19","author":"Nitta","year":"2013","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"4674","DOI":"10.4049\/jimmunol.1201654","article-title":"Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression","volume":"189","author":"Corrales","year":"2012","journal-title":"J. Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"84798","DOI":"10.18632\/oncotarget.12656","article-title":"C5a receptor (CD88) promotes motility and invasiveness of gastric cancer by activating RhoA","volume":"7","author":"Kaida","year":"2016","journal-title":"Oncotarget"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.3892\/or.2014.3489","article-title":"C5a stimuLates the proliferation of breast cancer cells via Akt-dependent RGC-32 gene activation","volume":"32","author":"Lu","year":"2014","journal-title":"Oncol. Rep."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.3892\/or.2014.3341","article-title":"Cancer cells release anaphylatoxin C5a from C5 by serine protease to enhance invasiveness","volume":"32","author":"Nitta","year":"2014","journal-title":"Oncol. Rep."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.3892\/or.2014.3420","article-title":"C5a promotes the proliferation of human nasopharyngeal carcinoma cells through PCAF-mediated STAT3 acetylation","volume":"32","author":"Cai","year":"2014","journal-title":"Oncol. Rep."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.4049\/jimmunol.1200846","article-title":"Opposing roles for complement component C5a in tumor progression and the tumor microenvironment","volume":"189","author":"Gunn","year":"2012","journal-title":"J. Immunol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.celrep.2014.02.014","article-title":"Autocrine effects of tumor-derived complement","volume":"6","author":"Cho","year":"2014","journal-title":"Cell. Rep."},{"key":"ref_51","first-page":"883","article-title":"Myeloid tumors and antitumor innate immunity","volume":"66","author":"Goyama","year":"2025","journal-title":"Rinsho Ketsueki"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Ma, Y., Zhang, L., and Liu, W. (2025). Immunosuppressive tumor microenvironment and advance in immunotherapy in melanoma bone metastasis. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1608215"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e012743","DOI":"10.1136\/jitc-2025-012743","article-title":"Positive and negative roles of myeloid cells in cancer immunotherapy","volume":"13","author":"Zak","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"149772","DOI":"10.1016\/j.gene.2025.149772","article-title":"Role of myeloid-derived suppressor cells in bladder cancer and targeted therapeutic strategies","volume":"970","author":"Boillat","year":"2025","journal-title":"Gene"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Chen, H., Xu, Z., and Varner, J. (2025). Targeting myeloid cells to improve cancer immune therapy. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1623436"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00432-025-06315-6","article-title":"Advancing our understanding of the influence of myeloid-derived suppressor cells in chronic myeloid leukemia","volume":"151","author":"Meng","year":"2025","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Huang, J., Ojo, A., Tsao, S., Horowitz, A., Kyprianou, N., and Tsao, C.K. (2025). Overcoming Immune Evasion in the Prostate Tumor Microenvironment: Novel Targeted Strategies to Improve Treatment Outcomes. Cancers, 17.","DOI":"10.3390\/cancers17213441"},{"key":"ref_58","unstructured":"Medof, M.E. Institute of Pathology, Case Western Reserve University, Cleveland, OH, USA, (manuscript in preparation; to be submitted)."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/11\/971\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T16:22:54Z","timestamp":1784650974000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/11\/971"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":58,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["cells15110971"],"URL":"https:\/\/doi.org\/10.3390\/cells15110971","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,25]]}}}